China's Groundbreaking AI-Driven Drug Gains Approval
Victor Chen | AA
China has approved its first AI-assisted 'Class 1' drug, Mprosevir, for COVID-19, a major milestone in the field of pharmaceutical innovation.
China has made a groundbreaking advancement in pharmaceuticals by approving its first artificial intelligence-assisted 'Class 1' innovative drug, marking a significant milestone in integrating AI into drug development.
The National Medical Products Administration (NMPA) has granted conditional marketing approval for Mprosevir, a drug designed to treat mild to moderate COVID-19 infections in adults. This achievement is noteworthy for advancing the use of AI in pharmaceutical research.
Mprosevir was created through a collaboration among Westlake University, Westlake Laboratory, and Westlake Pharmaceuticals, underscoring China's commitment to leveraging innovative technology in medicine.
Innovative Drug Development Process
The development of Mprosevir, which took just three and a half years from its initial discovery to the conclusion of clinical trials, highlights the efficacy of combining AI with traditional drug discovery methods. Its rapid development process stands as a testament to modern technological capabilities.
China categorizes 'Class 1' drugs as innovative medicines that have not been marketed anywhere before. Mprosevir holds the distinction of being the world's first small-molecule drug approved using DNA-encoded library (DEL) technology, showcasing China's pioneering role in pharmaceutical innovation.
Using DEL technology, researchers screened a massive library of about 49 billion compounds, initially identifying more than 100 prospective candidates. An AI model then narrowed this pool to nine candidates, dramatically accelerating the selection process.
Scientific Collaboration and Optimization
Westlake University led the efforts in the development of Mprosevir, integrating AI throughout the drug's development stages. The AI technology was pivotal in laboratory settings, animal studies, and advancing the drug towards clinical trials.
Through extensive testing, six molecules demonstrated strong activity, with WLU6937 emerging as the lead molecule. Subsequently, the research team spent about two years refining this molecule, meticulously ensuring its safety and efficacy.
This meticulous optimization process underscores the crucial role AI played, allowing researchers to streamline the drug development cycle significantly, marking a new era in pharmaceutical research and development.
Implications for Urban Health Policy
The approval of Mprosevir opens new avenues for urban health policy, particularly in large cities where the demand for effective COVID-19 treatments remains high. The integration of AI in drug development could lead to quicker access to innovative treatments for urban populations.
City policymakers are likely to view this advancement as a potential catalyst for deeper investments in AI technologies, fostering collaboration between tech companies and healthcare providers. This aligns with broader urban strategies to enhance public health infrastructure and emergency preparedness.
Questions That Matter
What is China's first AI-assisted drug?
China's first AI-assisted drug is Mprosevir, developed to treat mild to moderate COVID-19 infections. It was approved by China's National Medical Products Administration on September 2, 2026.
What technology was used to create Mprosevir?
Mprosevir was created using DNA-encoded library (DEL) technology. AI and DEL technology together screened a library of about 49 billion compounds to identify the most promising drug candidates.